In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment aimed at expanding its research and manufacturing footprint across the United States by the end of 2026. This strategic initiative underscores the company’s commitment to enhancing its presence in its largest market, which currently accounts for 44% […]
AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients with advanced nonsquamous non-small cell lung cancer (NSCLC). The study, conducted in collaboration with Daiichi Sankyo, compared datopotamab deruxtecan with docetaxel, the standard chemotherapy, revealing a median overall survival (OS) […]
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors exhibit exon 19 deletions or […]
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE (acalabrutinib) when combined with bendamustine and rituximab in treating previously untreated patients with mantle cell lymphoma (MCL). Presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain, the findings reveal a statistically significant and […]
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating next-generation radioconjugates (RCs) for cancer treatment. This strategic acquisition not only expands AstraZeneca’s capabilities in targeted cancer therapy but also consolidates its research and development footprint in North America. Financial […]
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical giant AstraZeneca. This enhanced partnership focuses on utilizing Tempus Next, a care pathway intelligence platform, to facilitate the delivery of biomarker testing for patients with non-small cell lung cancer (NSCLC), addressing critical care gaps. Enhancing Precision Medicine […]
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.’s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a special virtual meeting, approximately 80.83% of Fusion’s issued and outstanding shares were represented, with 99.92% of these votes endorsing the acquisition under the terms of a plan of arrangement as […]
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential as a treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). This trial marks a significant milestone as datopotamab deruxtecan, a TROP2-directed antibody drug conjugate (ADC), showed a clinically meaningful improvement in overall survival (OS) compared to […]
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept study led by AstraZeneca in partnership with Amgen, has revealed key findings about TEZSPIRE (tezepelumab) and its effects on COPD exacerbations. Despite a non-statistically significant overall reduction, a notable subgroup analysis showed potential benefits for patients with […]
In a significant development, UK-based pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, known as Covishield in India and Vaxzevria in other markets. This decision comes shortly after the company admitted in court documents that the vaccine could cause a rare but severe side effect known as Thrombosis Thrombocytopenia Syndrome (TTS). […]